

DRUGS THAT INHIBIT SIGNALING PATHWAYS FOR TUMOR CELL GROWTH AND PROLIFERATION

KINASE INHIBITORS

10

CONTENTS

1. Introduction	392
2. Oncogenes and signal transduction	393
3. The role of protein kinases in cancer: signaling pathways related to kinases	394
4. Inhibitors of tyrosine kinases	402
4.1. Inhibitors of EGFR (HER-1)	403
4.1.1. <i>Small-molecule EGFR inhibitors</i>	405
4.1.2. <i>Monoclonal antibodies acting as inhibitors of EGFR</i>	409
4.2. Inhibitors of HER-2	410
4.3. Inhibitors of HER-3	411
4.4. Pan-HER inhibitors	411
4.5. Inhibitors of insulin-like growth factor receptors (IGF-1R)	411
4.6. Inhibitors of hepatocyte growth factor receptor (HGFR, c-Met)	413
4.7. Inhibitors of Pro-angiogenic tyrosine kinases: vascular endothelial growth factor receptor and related kinase receptors	413
4.7.1. <i>VEGFR inhibitors</i>	414
4.7.2. <i>Other types of anti-VEGF therapy</i>	419
4.7.3. <i>Inhibitors of PDGFRs</i>	420
4.7.4. <i>Fibroblast growth factor receptor (FGFR) inhibitors</i>	420
4.8. Inhibitors of FLT3 (CD135)	421
4.9. Inhibitors of Bcr-Abl tyrosine kinase (Abelson kinase)	422
4.9.1. <i>Compounds acting as ATP mimics</i>	422
4.9.2. <i>Compounds acting as tyrosine mimics</i>	426
4.9.3. <i>Dual inhibitors of Bcr-Abl and Src tyrosine kinases</i>	426
4.9.4. <i>Inhibitors of Bcr-Abl biosynthesis</i>	427
4.10. Anaplastic lymphoma kinase (ALK) inhibitors	427
4.11. Inhibitors of JAK–STAT and PRL pathways	431